TMCnet News

Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"
[November 18, 2014]

Opexa Therapeutics Selected as One of the "Top 10 Advanced Therapy Projects to Watch"


THE WOODLANDS, Texas --(Business Wire)--

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the "Top 10 Advanced Therapy Projects to Watch" by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa's President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider among the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

"We are honored to be chosen for the second year as one of the top ten advanced therapies by Elsevier," stated Mr. Warma. "We believe this recognition speaks to the potential Tcelna® holds for the treatment of secondary progressive MS, as well as to Opexa's position as a leader in the field of personalized medicine."

About Opexa

Opexa is a biopharmaceutical company developing personalized immunotherapies wth the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patient's peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin. Opexa's mission is to lead the field of Precision Immunotherapy® by aligning the interests of patients, employees and shareholders.



For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Forward-Looking Statements


Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as Tcelna® and OPX-212 constitute forward-looking statements. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation our ability to raise additional capital to continue our development programs, our ability to successfully develop potential products such as Tcelna, our ability to obtain, maintain and protect intellectual property rights (including for Tcelna and future pipeline candidates such as OPX-212), as well as other risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in our SEC (News - Alert) filings, including our Annual Report on Form 10-K for the year ended December 31, 2013 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. All forward-looking statements contained in this release speak only as of the date on which they were first made by us, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after such date.


[ Back To TMCnet.com's Homepage ]